Navigation Links
Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology

Data Supports Use of HIV-specific T cell Precursors with High Proliferative

Capacity (PHPC) Marker to Predict Reduction of Viral Load

MCLEAN, Va., and BUDAPEST, Hungary, April 21 /PRNewswire/ -- Genetic Immunity(R), a US/Hungarian clinical-stage company focused on patented nanomedicines for immune amplification, announced today that the Journal of Immunology published findings on a key biomarker currently being used in clinical studies of its lead HIV/AIDS nanomedicine candidate, the DermaVir Patch. The paper, entitled "HIV-1-Specific T-Cell Correlate with Low Viremia and High CD4 Counts in Untreated Individuals," highlights data from a study conducted by Sandra Calarota, Ph.D., of the Research Institute for Genetic and Human Therapy (RIGHT).

In Dr. Calarota's study of 32 HIV-1 infected individuals, high immunological responses measured by a novel assay of T cell Precursors with High Proliferative Capacity (PHPC assay) better correlated with viral suppression and positive immunologic outcomes, than did the traditional ELISPOT assay.

These data further validate and support results from a clinical study of Genetic Immunity's DermaVir Patch presented in February 2008 at the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI). The study demonstrated that the DermaVir Patch induced a significant increase of PHPC counts in all 9 HIV-1-infected participants, suggesting that the DermaVir Patch may promote a targeted amplification of the immune system capable of reducing the amount of circulating HIV virus.

Dr. Franco Lori, the lead author of the study said, "The correlation between high PHPC counts and low viral load in HIV-infected subjects suggests that the presence of a greater number of T-cells that have retained their ability to expand and function normally may be a better predictor of patient outcomes. This new PHPC assay may also be a valuable tool in the development and testing of urgently needed nanomedicines, immune therapies and prophylactic vaccines for a number of diseases in addition to HIV/AIDS."

Julianna Lisziewicz, Ph.D., Co-Founder and CEO of Genetic Immunity, said, "The design and testing of the DermaVir Patch has long focused on PHPCs as a marker. We see these results as validation that our approach has been scientifically sound.

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immunity amplification. next-generation biopharmaceuticals. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. The Company is leveraging its proprietary immune amplification platform technology, Genetic Immunity aims to create new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. Genetic Immunity's founders discovered the lead product nanomedicine candidate, the DermaVir Patch for the treatment of HIV/AIDS. The DermaVir Patch is in Phase II clinical development and could be the first nanomedicine immune therapy approved for HIV-infected individuals. DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific T cells.

About the Nanomedicine Technology Platform

Genetic Immunity's immune amplification platform technology is used to develop nanomedicines comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can alleviate a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.


The Ruth Group

Investors Media

Sara Ephraim Janine McCargo

+1-646-536-7002 +1-646-536-7033

SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
2. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
3. Navigenics(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
4. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
5. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
6. Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)
7. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
8. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
9. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
10. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):